| Variables | |
| Female, (%) | 122 (46.7) | Age (years), mean (SD) | 56.13 (15.8) | BMI (), mean (SD) | 27.1 (6.1) | Lifestyle | | Smokers (), (%) | 50 (19.2) | Current alcohol (), (%) | 129 (49.4) | Overuse alcohol, (%) | 42 (16.1) | Etiology of liver disease | | Hepatitis B, (%) | 79 (30.3) | Liver cirrhosis, (%) | 64 (24.5) | Alcoholic liver disease, (%) | 63 (24.1) | Nonalcoholic fatty liver disease, (%) | 52 (19.9) | Hemochromatosis, (%) | 23 (8.8) | Alcoholic liver insufficiency, (%) | 19 (7.3) | Chronic liver insufficiency, (%) | 17 (6.5) | Hepatitis C, (%) | 15 (5.7) | Autoimmune hepatitis, (%) | 9 (3.4) | Hepatocellular carcinoma, (%) | 9 (3.4) | Primary biliary cholangitis, (%) | 8 (3.1) | Alfa-1-antitrypsin deficiency, (%) | 6 (2.3) | Wilsons, (%) | 1 (0.4) | Primary sclerosing cholangitis, (%) | 1 (0.4) | Budd-Chiari, (%) | 1 (0.4) | Comorbidities | | Obesity, (%) | 72 (27.6) | Hypertension, (%) | 63 (24.1) | Type 2 diabetes, (%) | 53 (20.3) | Cardiac disease, (%) | 38 (14.6) | Autoimmune diseases, (%) | 37 (14.2) | Chronic pulmonary disease, (%) | 32 (12.3) | History of stroke or hemiplegia, (%) | 15 (5.7) | Asthma, (%) | 11 (4.2) | Localized solid tumor, (%) | 11 (4.2) | Chronic kidney disease, (%) | 9 (3.4) | Dementia, (%) | 6 (2.3) | No comorbidities, (%) | 99 (37.9) | Charlson Comorbidity Index, mean (SD) | 3.26 (2.5) | Number of hospital admissions in the last 12 months prior to COVID-19 diagnosis, mean (SD) | 1.0 (2.6) | Hospitalization length (cumulated), median (IQR) | 13 (3-33.50) | Biochemistry in plasma | | Hemoglobin, mean (SD) | 8.2 (1.3) | Platelet (×109/L), mean (SD) | 219 (97.7) | ALAT (U/L), mean (SD) | 40.9 (35.1) | Albumin (g/dL), mean (SD) | 34.8 (8.1) | Bilirubin (μmol/L), mean (SD) | 17 (29.4) | INR, mean (SD) | 1.1 (0.3) | Creatinine (μmol/L), mean (SD) | 89.8 (110.7) | Sodium (mmol/L), mean (SD) | 137.3 (11) | C-reactive protein (mg/dL), mean (SD) | 11.2 (24.6) | Treatment () | | Specific medication therapy of CLD | | Vitamin B, (%) | 44 (16.9) | Furosemide, (%) | 32 (12.3) | Spironolactone, (%) | 29 (11.0) | Venesection, (%) | 16 (6.1) | Antiviral nucleos(t)ide analogues, (%) | 14 (5.4) | Propranolol, (%) | 10 (3.8) | Nutrients (calcium, vitamin D, zinc, magnesium, etc.), (%) | 7 (2.7) | Ursodeoxycholic acid, (%) | 7 (2.7) | Rifaximin, (%) | 6 (2.3) | Albumin infusion, (%) | 5 (1.9) | Ciprofloxacin (SBP prophylaxis), (%) | 4 (1.5) | Anticoagulation therapy, (%) | 3 (1.1) | Prednisolone, (%) | 3 (1.1) | Immune modulation, (%) | 2 (0.8) |
|
|